Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mesohyal argibenone is a professional anti-aging and antioxidant intradermal injectable solution, developed by Mesoestetic, combining non-crosslinked hyaluronic acid (15 mg/ml), acetyl hexapeptide-8 (a biomimetic peptide also known as argireline), and idebenone (a potent antioxidant akin to coenzyme Q10)[1][2][4][5][7]. The preparation acts by hydrating and plumping skin (hyaluronic acid), reducing dynamic facial wrinkles through the reversible inhibition of acetylcholine exocytosis (acetyl hexapeptide-8, which acts similarly to botulinum toxin by blocking neuromuscular transmission), and protecting cells/DNA against oxidative stress and photoaging (idebenone protects against lipid/protein oxidation and supports mitochondrial function)[1][2][4]. Indicated for facial rejuvenation, wrinkle reduction, photoaging, and improving skin firmness primarily on the face, neck, and décolletage, it is for professional use only via intradermal injection. Typical regimens involve five sessions at 15-day intervals, with effects lasting up to 9 months[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mesohyal argibenone.